Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Prostate selectivity of JTH‐601‐G1, an active metabolite of JTH‐601, in dogs

View through CrossRef
Objective To evaluate the effect of JTH‐601‐G1, an active metabolite and glucuronide conjugate of JTH‐601 (an α 1 ‐adrenoceptor antagonist), on smooth muscle contraction in canine prostate and artery, and to examine the effect of JTH‐601‐G1 on prostatic urethral pressure and blood pressure in anaesthetized dogs. Materials and methods Male beagle dogs were used in both an in vitro and an in vivo study. In the former, the prostate and right common carotid artery were isolated, and smooth muscle strips from the prostate and open‐ring strips from the carotid artery prepared. The effects of JTH‐601‐G1 on phenylephrine‐ and noradrenaline‐induced contraction were assessed in these tissues. In the in vivo study, four dogs were anaesthetized and the change in urethral pressure, blood pressure and heart rate measured continuously. Vehicle (saline) and JTH‐601‐G1 were then infused intravenously in increasing doses (0.33–3.3 µg/kg/min for 30 min). In three other dogs, the effect of JTH‐601‐G1 infusion at a higher rate (25 µg/kg/min for 3 h) on blood pressure was evaluated, and the plasma concentration of JTH‐601‐G1 measured using high‐performance liquid chromatography‐mass spectrometry. Results Of the distinct metabolites of JTH‐601, JTH‐601‐G1 had the most potent α 1 ‐adrenoceptor antagonistic effect in isolated canine prostate. JTH‐601‐G1 also antagonized α 1 ‐adrenoceptor agonist‐induced contraction in common carotid artery, but the pA 2 value in the artery was ≈25 times higher than that in the prostate. In anaesthetized dogs, JTH‐601‐G1 decreased urethral pressure in a dose‐dependent manner; at the highest dose, urethral pressure decreased by 24.5% and blood pressure by 7.0%. However, there was no significant change in heart rate at any dose. The plasma concentration of JTH‐601‐G1 increased with the dose of JTH‐601‐G1, but the concentration of both JTH‐601 and other metabolites was below the detection limit. The higher JTH‐601‐G1 infusion rate caused blood pressure to decrease by only 6–10% even at JTH‐601‐G1 plasma concentrations of ≈1500 ng/mL during the infusion. Although there was a negative correlation between mean blood pressure and plasma JTH‐601‐G1 concentration, the decrease in blood pressure was small compared with the reduction in urethral pressure. Conclusion JTH‐601‐G1 appears to be a major active metabolite of JTH‐601 but with a higher selectivity for canine prostate than artery. The results also indicate that in addition to the α 1A ‐adrenoceptor, the α 1L ‐adrenoceptor plays an important prostatic selective role in smooth muscle contraction via the α 1 ‐adrenoceptor.
Title: Prostate selectivity of JTH‐601‐G1, an active metabolite of JTH‐601, in dogs
Description:
Objective To evaluate the effect of JTH‐601‐G1, an active metabolite and glucuronide conjugate of JTH‐601 (an α 1 ‐adrenoceptor antagonist), on smooth muscle contraction in canine prostate and artery, and to examine the effect of JTH‐601‐G1 on prostatic urethral pressure and blood pressure in anaesthetized dogs.
Materials and methods Male beagle dogs were used in both an in vitro and an in vivo study.
In the former, the prostate and right common carotid artery were isolated, and smooth muscle strips from the prostate and open‐ring strips from the carotid artery prepared.
The effects of JTH‐601‐G1 on phenylephrine‐ and noradrenaline‐induced contraction were assessed in these tissues.
In the in vivo study, four dogs were anaesthetized and the change in urethral pressure, blood pressure and heart rate measured continuously.
Vehicle (saline) and JTH‐601‐G1 were then infused intravenously in increasing doses (0.
33–3.
3 µg/kg/min for 30 min).
In three other dogs, the effect of JTH‐601‐G1 infusion at a higher rate (25 µg/kg/min for 3 h) on blood pressure was evaluated, and the plasma concentration of JTH‐601‐G1 measured using high‐performance liquid chromatography‐mass spectrometry.
Results Of the distinct metabolites of JTH‐601, JTH‐601‐G1 had the most potent α 1 ‐adrenoceptor antagonistic effect in isolated canine prostate.
JTH‐601‐G1 also antagonized α 1 ‐adrenoceptor agonist‐induced contraction in common carotid artery, but the pA 2 value in the artery was ≈25 times higher than that in the prostate.
In anaesthetized dogs, JTH‐601‐G1 decreased urethral pressure in a dose‐dependent manner; at the highest dose, urethral pressure decreased by 24.
5% and blood pressure by 7.
0%.
However, there was no significant change in heart rate at any dose.
The plasma concentration of JTH‐601‐G1 increased with the dose of JTH‐601‐G1, but the concentration of both JTH‐601 and other metabolites was below the detection limit.
The higher JTH‐601‐G1 infusion rate caused blood pressure to decrease by only 6–10% even at JTH‐601‐G1 plasma concentrations of ≈1500 ng/mL during the infusion.
Although there was a negative correlation between mean blood pressure and plasma JTH‐601‐G1 concentration, the decrease in blood pressure was small compared with the reduction in urethral pressure.
Conclusion JTH‐601‐G1 appears to be a major active metabolite of JTH‐601 but with a higher selectivity for canine prostate than artery.
The results also indicate that in addition to the α 1A ‐adrenoceptor, the α 1L ‐adrenoceptor plays an important prostatic selective role in smooth muscle contraction via the α 1 ‐adrenoceptor.

Related Results

Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract The human olfactomedin 4 gene (OLFM4) encodes an olfactomedin-related glycoprotein, which our group first cloned and characterized in myeloid cells and mapp...
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Background: Early prostate cancer antigen (EPCA), a nuclear matrix protein, has recently been recommended as a hopeful biomarker for early prostate carcinogenesis. Objectives: To e...
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract BACKGROUND: Multiple steps and factors are involved in prostate carcinogenesis and tumor progression. The early studies have found that tumor-associated mac...
Exercise-induced cardiac remodeling in farm dogs: A comparative echocardiographic and electrocardiographic study
Exercise-induced cardiac remodeling in farm dogs: A comparative echocardiographic and electrocardiographic study
<b>Objectives:</b> To compare cardiac structure and function of healthy indoor dogs, healthy active farm dogs, and indoor dogs with structural heart disease, and to inv...
Oxidative stress biomarkers in hypothyroid, non thyroid illness and euthyroid dogs
Oxidative stress biomarkers in hypothyroid, non thyroid illness and euthyroid dogs
Abstract There are only a few numbers of published reports available on oxidative stress parameters in hypothyroidism and many of which are in the field of human me...
Analysis of the spatial distribution and clinical features of prostate cancer in transperineal prostate biopsy
Analysis of the spatial distribution and clinical features of prostate cancer in transperineal prostate biopsy
Abstract Background Recently, most studies on the spatial distribution of the prostate cancer are based on the samples confirmed by transrectal prostate biopsy (TRBx), whic...

Back to Top